

Table of Contents

Guest Editor for this issue:

Omar A. Minai, MD

Department of Pulmonary,
Allergy and Critical Care Medicine
Cleveland Clinic
Cleveland, Ohio

- 117 Profiles in Pulmonary Hypertension:
Emmanuel Weitzenblum, MD
- 118 Ask the Expert
- 120 Article Reviews
- 129 Advances in Pulmonary Hypertension CME Section
- 131 Pulmonary Hypertension in Obstructive Sleep Apnea Syndrome
- 141 Diagnosis and Management of Pulmonary Hypertension Associated with Pulmonary Fibrosis
- 148 Pulmonary Hypertension Associated with Sarcoidosis
- 156 Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease: Diagnosis and Management
- 161 CME Self-Assessment Examination
- 163 Pulmonary Hypertension Roundtable: PAH in Patients with Lung Disease and Hypoxia
- 176 Clinical Trials Update
- 178 PHRN Corner

Publisher

Pulmonary Hypertension Association
Carl Hicks, *Board Chair*
Rino Aldrighetti, *President*

Publishing Staff

Managing Editor
Deborah L. McBride
McBride Strategic Services
mcbridedeb@aol.com
Design Director
Michael McClain

PHA Office

Pulmonary Hypertension Association
801 Roeder Road., Ste 400
Silver Spring, MD 20910
301-565-3004, 301-565-3994 (fax)
www.PHAAssociation.org

© 2009 by Pulmonary Hypertension Association. All rights reserved. None of the contents may be reproduced in any form whatsoever without the written permission of PHA.

Advances in Pulmonary Hypertension is circulated to cardiologists, pulmonologists, rheumatologists and other selected physicians by the Pulmonary Hypertension Association. The contents of the articles are independently determined by the Editor and the Editorial Advisory Board.

Cover Image

Charles Dickens' character Joe from *The Posthumous Papers of the Pickwick Club* is the source of the term Pickwickian Syndrome, or obesity hypoventilation syndrome. He is depicted on the cover in an illustration by David Zwierz.

Guest Editor's Memo

Translating Evidence into Clinical Practice



Pulmonary hypertension (PH) associated with lung disease and hypoxia (WHO Group III) is one of the most common forms of pulmonary hypertension. It also encompasses a very diverse group of diseases where the PH is an extremely important determinant of functional limitation and prognosis. In this group of diseases, PH is common in advanced disease, however its prevalence in milder disease is not known. None of the non-invasive screening methods have been found to be accurate and the best screening tool, Doppler echocardiography, is especially prone to error. Treating these patients

can be a frustrating experience because of the lack of prospective trials and the associated underlying lung disease. Several questions remain unanswered including the populations to be screened, best diagnostic approach, and treatment options. In the current issue of *Advances*, all these questions have been addressed by some of the key thought-leaders in this field.

In our article on PH in Obstructive Sleep Apnea (OSA), Dr Chua and I have tried to summarize the clinically relevant literature on pulmonary hemodynamics in patients with OSA. We point out that PH in OSA is a multi-factorial process and may have important implications in terms of functional capacity and prognosis in these patients. CPAP therapy may be helpful in patients with mild PH, however more studies are needed to better define the role of PH-specific therapy in patients with more significant PH.

The articles by Dr Klinger on PH in interstitial lung diseases, Dr Girgis on PH in sarcoidosis, and Dr Preston on PH in COPD all provide an exhaustive yet focused review of the literature. These authors make several recommendations that readers can utilize in their clinical practice in terms of diagnostic evaluation and when faced with various treatment dilemmas.

The roundtable is hosted by me and discussants are Drs Nicholas Hill and Steve Nathan, who bring a wealth of experience and wisdom to the discussion. During the

(continued on page 160)

Editor's Memo



It is with great excitement that I introduce the Fall 2009 issue of *Advances*, devoted to pulmonary hypertension in the setting of lung or respiratory disease (or WHO Diagnostic Group III). Dr Omar Minai has done an outstanding job of coordinating the issue and contributing one of the articles.

The topic of pulmonary hypertension in patients with underlying pulmonary disorders is critical. What are the mechanisms involved in the development of PH in these patients? How common is PH in this group? How severe? When can we attribute PH in an individual patient to the underlying pulmonary disease and when is the PH "out of proportion"? And importantly, can we treat any of these patients with PAH-specific therapies?

This last question is, indeed, a charged topic. In reality, PAH-specific drugs are already being used in patients with underlying pulmonary disease. Does this represent inappropriate, off-label use of costly therapies, or thoughtful, albeit empiric, application of targeted treatment to patients who may share many of the histopathologic features with more "typical" PAH patients? The truth, of course, is probably somewhere in the middle, but what are the data?

As someone who lectures widely on all aspects of pulmonary hypertension, I am asked after virtually every talk whether the current PAH therapies are ever indicated in patients with PH and underlying lung or respiratory disease, especially COPD. This is not a surprising question. After all, these are the patients that physicians see. A community-based pulmonologist rarely ever sees a 30-year-old woman with idiopathic pulmonary arterial hypertension. What he or she sees regularly is a 65-year-old overweight patient with some underlying sleep apnea, hypertension, and COPD. Some

(continued on page 160)

Editorial Advisory Board

Editor-in-Chief

Richard Channick, MD
Director, Pulmonary Hypertension Program
Massachusetts General Hospital
Boston, Massachusetts

Immediate Past Editor

Ronald J. Oudiz, MD
Associate Professor of Medicine
The David Geffen School of Medicine at UCLA
Director, Liu Center for Pulmonary Hypertension
LA Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, California

Editor-in-Chief Elect

Erika Berman Rosenzweig, MD
Associate Professor of Clinical Pediatrics (in Medicine)
Columbia University, College of Physicians and Surgeons
Morgan Stanley Children's Hospital of New York
New York, New York

Associate Editors

Kristin Highland, MD
Assistant Professor of Medicine
Division of Pulmonary, Critical Care, Allergy and Sleep Medicine
Medical University of South Carolina
Charleston, South Carolina

Francisco Soto, MD, MS

Director, Pulmonary Hypertension Program
Pulmonary and Critical Care Medicine
Medical College of Wisconsin
Milwaukee, Wisconsin

Todd Bull, MD

Associate Professor of Medicine
Division of Pulmonary Sciences and Critical Care Medicine
University of Colorado Health Sciences Center
Denver, Colorado

Robert Schilz, DO, PhD

Medical Director of Lung Transplantation and Pulmonary Vascular Disease
University Hospital of Cleveland
Case Western Reserve University
Cleveland, Ohio

Editorial Board

Charles Burger, MD
Chair, Pulmonary and Critical Care Medicine
Associate Professor of Medicine
Medical Director, PH Clinic
Mayo Clinic Florida
Jacksonville, Florida

Karen Fagan, MD

Chief, Division of Pulmonary and Critical Care Medicine
University of South Alabama
Mobile, Alabama

Eli Gabbay, MD

Lung Transplant Unit
Royal Perth Hospital
Western Australia, Australia

Nick Kim, MD

Associate Clinical Professor of Medicine
University of California, San Diego
La Jolla, California

Deborah Jo Levine, MD

University of Texas Health Science Center at San Antonio
San Antonio, Texas

Omar A. Minai, MD

Dept of Pulmonary, Allergy and Critical Care Medicine
Cleveland Clinic
Cleveland, Ohio

Myung Park, MD

Assistant Professor of Medicine
Director, Pulmonary Vascular Diseases Program
Division of Cardiology
University of Maryland School of Medicine
Baltimore, Maryland

Fernando Torres, MD

Director, Pulmonary Hypertension Clinic
University of Texas Southwestern Medical Center
Dallas, Texas

Glenna Traiger, RN, MSN

Pulmonary & Critical Care
Pulmonary Hypertension CNS
University of California, Los Angeles
Los Angeles, California

R. James White, MD, PhD

Assistant Professor of Medicine, Pharmacology & Physiology
Division of Pulmonary and Critical Care Medicine
University of Rochester
Rochester, New York

Roham Zamanian, MD

Division of Pulmonary and Critical Care Medicine
Stanford University Medical Center
Stanford, California

Program Description

The mission of *Advances in Pulmonary Hypertension* is to serve as the premiere forum for state of the art information regarding diagnosis, pathophysiology, and treatment of pulmonary hypertension. The 2008 Dana Point revision of the World Health Organization Classification serves as a guide to categories of pulmonary hypertension addressed in *Advances in Pulmonary Hypertension*. While focusing on WHO Group I PAH, the other categories (Group II, pulmonary venous hypertension; Group III, Associated with chronic lung disease and/or hypoxemia; Group IV, pulmonary embolic hypertension; Group V, Miscellaneous) are also addressed. This mission is achieved by a combination of invited review articles, Roundtable discussions with panels consisting of international experts in PH, and original contributions. In addition, a special section in selected issues entitled "Profiles in Pulmonary Hypertension" recognizes major contributors to the field and serves as an inspiring reminder of the rich and collegial history of dedication to advancing the field.

Objectives

- Provide up-to-date information regarding diagnosis, pathophysiology, and treatment of pulmonary hypertension.
- Serve as a forum for presentation and discussion of important issues in the field, including new paradigms of disease understanding and investigational trial design.
- Recognize and preserve the rich history of individuals who have made major contributions to the field via dedication to patient care, innovative research, and furthering the mission of the PH community to cure pulmonary hypertension.

The Scientific Leadership Council of the Pulmonary Hypertension Association

The scientific program of the Pulmonary Hypertension Association is guided by the association's Scientific Leadership Council. The Council includes the following health care professionals:

Vallerie V. McLaughlin, MD

Chair, SLC
University of Michigan
Health System
Ann Arbor, Michigan

David B. Badesch, MD

SLC Immediate Past-Chair
University of Colorado Health Sciences Center
Aurora, Colorado

John H. Newman, MD

SLC Vice-Chair
Vanderbilt Medical School
Nashville, Tennessee

Raymond L. Benza, MD

Allegheny General Hospital
Pittsburgh, Pennsylvania

Todd Bull, MD

University of Colorado Health Sciences Center
Denver, Colorado

Richard Channick, MD

Editor-in Chief, *Advances in Pulmonary Hypertension*
Massachusetts General Hospital
Boston, Massachusetts

C. Gregory Elliott, MD

University of Utah School of Medicine
Murray, Utah

Karen A. Fagan, MD

University of South Alabama
Mobile, Alabama

Robert Frantz, MD

Mayo Clinic College of Medicine
Rochester, Minnesota

John Granton, MD

Toronto General Hospital
Toronto, Canada

Nicholas S. Hill, MD

Tufts-New England Medical Center
Boston, Massachusetts

Marius Hoeper, MD

University of Hanover Medical School
Hanover, Germany

Dunbar Ivy, MD

University of Colorado
Denver Health Sciences Center
Denver, Colorado

Zhi-Cheng Jing, MD

Shanghai Pulmonary Hospital
Shanghai, China

Anne M. Keogh, MD

St. Vincent's Public Hospital
Sydney, Australia

Michael J. Krowka, MD

Mayo Clinic
Rochester, Minnesota

James E. Loyd, MD

Vanderbilt University Medical Center
Nashville, Tennessee

Michael Mathier, MD

University of Pittsburgh
Medical Center
Pittsburgh, Pennsylvania

Michael D. McGoon, MD

Immediate Past-Chair,
PHA Board of Trustees
Mayo Clinic
Rochester, Minnesota

Srinivas Murali, MD

Allegheny General Hospital
Pittsburgh, Pennsylvania

Ronald J. Oudiz, MD

Immediate Past Editor-in-Chief,
Advances in Pulmonary Hypertension
Liu Center for Pulmonary Hypertension at Harbor – UCLA Medical Center
Torrance, California

Andrew Peacock, MD

Western Infirmary
Glasgow, Scotland, United Kingdom

Erika Berman Rosenzweig, MD

Editor-In-Chief Elect, *Advances in Pulmonary Hypertension*
Columbia Presbyterian Medical Center
New York, New York

Ivan Robbins, MD

Chair, Scientific Sessions Committee
Vanderbilt University
Nashville, Tennessee

Julio Sandoval, MD

National Institute of Cardiology of Mexico
Tlalpan, Mexico

Richard Silver, MD

Medical University of South Carolina
Charleston, South Carolina

Victor F. Tapson, MD

Duke University Medical Center
Durham, North Carolina

Jason Yuan, MD, PhD

Chair, PHA Research Committee
University of California, San Diego
La Jolla, California

Liaisons

Arlene Schiro, NP (voting)

Chair, PH Resource Network
Massachusetts General Hospital
Boston, MA

Harry Rozakis

Board Liaison

Emeritus Members

Bruce H. Brundage, MD

St. Charles Medical Center - Bend
Bend, Oregon

Alfred P. Fishman, MD

University of Pennsylvania
Health System
Philadelphia, Pennsylvania

The Mission of the Scientific Leadership Council is to provide medical and scientific guidance and support to the PHA by:

- Developing and disseminating knowledge for diagnosing and treating pulmonary hypertension
- Advocating for patients with pulmonary hypertension
- Increasing involvement of basic and clinical researchers and practitioners

More information on PHA's Scientific Leadership Council and associated committees can be found at: www.PHAAssociation.org/SLC/